Clinical AI Diagnostics Platform
Add a protocol, not another product.
AI Suite™ is the workflow layer behind SaveLife.AI. The Spine composes scribe notes, imaging AI, PACS, EHR data, and registry fields onto one screen, reconfigured per specialty, with zero reinvention.
The moat
The Spine.
Everyone else owns a layer. We own the composition. The Spine carries patient context from the encounter to the scan to the next order. Same patient. Same timeline. Same source of truth.
Platform Performance
FDA 510(k) Cleared · NeuroICH K241719 · HITRUST CSF Certified · HIPAA Compliant
Composability you can see
One screen, reconfigured per specialty.
Click a workflow. The shell stays put, the AI imaging model, extraction preset, and registry reconfigure.
Click a vertical. Watch the highlighted regions swap. Everything else stays.
- History of Present Illness
- Patient History
- NIHSS & Neuro Exam
- Imaging Documentation
- Labs
- Clinical Impression
- Thrombolytic Decision
Patient states he’s had a cough for about two weeks. Describes it as dry, more noticeable at night. Reports mild shortness of breath with exertion…
You just saw a stroke workflow. Click STEMI. Click Personal Injury. The shell didn’t change. The AI extraction did. The image module did. The registry did. That’s composability you can see.
Product Features
Explore AI Suite™ Features
Everything AI Suite™ can do, click any feature to see it in action.
Instant AI Detection for Cerebral Hemorrhage
Rapidly flagging bleeds in brain imaging, helping clinicians intervene early.
AI Modules
Five AI modules. One platform.
Each module plugs into the same standardized framework, deploy one or all five.
NeuroICH™
Intracranial Hemorrhage Detection
Modality: CT Head (non-contrast)
NeuroICH™ detects intracranial hemorrhage (ICH) on non-contrast head CT scans in under 60 seconds, delivering critical physician alerts in less than 30 seconds after scan acquisition. Cleared under FDA 510(k) K241719, November 7, 2024.
Key Performance Metrics
- ✓97.5% sensitivity, 90.3% accuracy
- ✓Detects IPH, IVH, SAH, SDH, and EDH
- ✓Alerts in < 30 seconds after scan acquisition
- ✓160% productivity increase, 52 vs 20 scans/day
- ✓+30% ED throughput improvement
- ✓Validated across Siemens, Philips, and more
- ✓Available FREE for all LMICs
- ✓$8 return per $1 invested
MammoSightAI™
Early Breast Cancer Detection
Modality: Mammography (2D and 3D/Tomosynthesis)
MammoSightAI™ detects breast abnormalities with 96.1% sensitivity, versus 85% with traditional methods, enabling detection up to 4+ years earlier. Designed to reduce missed diagnoses and integrate cleanly into mammography workflows.
Key Performance Metrics
- ✓96.1% sensitivity vs. 85% traditional
- ✓4+ years earlier cancer detection
- ✓$33B saved yearly (estimated potential)
- ✓ROI: $5 return per $1 invested
- ✓2D and 3D/Tomosynthesis support
- ✓Actionable insights to reduce missed diagnoses
FDA 510(k) Clearance Documents, K252954
DenseViewAI™
Automated Breast Density Assessment
Modality: Mammography
DenseViewAI™ automates breast density assessment with 82–99% agreement in under 2 seconds per study. Compliance-ready for 38-state density notification requirements. Adds up to $1.8M annual revenue per radiologist.
Key Performance Metrics
- ✓82–99% density assessment agreement
- ✓< 2 seconds per study
- ✓41% increase in cancer detection
- ✓25–35% productivity increase
- ✓4,500–6,000 additional studies/year per radiologist
- ✓38-state density notification compliance
CXRDetectAI™
Chest X-Ray Abnormality & TB Detection
Modality: Chest Radiograph
CXRDetectAI™ detects chest X-ray abnormalities including pneumonia, nodules, and pulmonary effusion, with 94% sensitivity versus 65% manual detection. Identifies tuberculosis with 90% sensitivity and specificity, reducing missed findings by 83%.
Key Performance Metrics
- ✓94% sensitivity vs. 65% manual
- ✓90% TB sensitivity and specificity
- ✓83% fewer missed findings
- ✓33% time reduction per study
- ✓$48,000 daily cost avoidance per 100 studies
- ✓Probability-based output with localization markers
NeuroLVO™
Large Vessel Occlusion Detection
Modality: CT/CTA Head
NeuroLVO™ rapidly identifies large vessel occlusions for stroke management, notifying clinicians in under 58 seconds. With 90%+ sensitivity and specificity, it increases thrombectomy eligibility by 23% and improves functional outcomes.
Key Performance Metrics
- ✓90%+ sensitivity and specificity
- ✓< 58 seconds notification time
- ✓23% increase in thrombectomy eligibility
- ✓78.7% faster image interpretation
- ✓32-minute door-to-groin time reduction
- ✓35% mortality reduction (golden-hour treatment)
Architecture
Built on a five-layer AI platform
AI Suite embeds directly into RadioViewAI or deploys standalone via ConnectAI, the same standardized framework for every module.
Audit System
FDA compliance tracking, performance monitoring
Output Interface
Probability scores, localization, visual markers
Module Framework
Standardized API, internal + third-party modules
Processing Engine
Scalable compute, sub-minute analysis
Integration Layer
DICOM PACS/RIS via ConnectAI™
AI Suite supports external third-party AI detection modules alongside SaveLife.AI’s own modules, enabling facilities to use AI Suite as their single AI orchestration layer regardless of AI vendor.
Trusted & Certified
Built for Healthcare Compliance
99.41% breach-free rate · Zero-Trust Architecture · FDA 510(k) Cleared, NeuroICH™ K241719
FDA-cleared AI diagnostics for your facility
Deploy NeuroICH™ today and access the full AI Suite pipeline as modules receive FDA clearance.
Book a Demo